ForSight Robotics is a technology company.
ForSight Robotics has raised $195.0M across 3 funding rounds.
ForSight Robotics has raised $195.0M in total across 3 funding rounds.
ForSight Robotics has raised $195.0M in total across 3 funding rounds.
ForSight Robotics's investors include Accel, Eclipse Ventures, Sonder Capital, Jeff Crusey, Borealis Ventures, Mithril Capital Management, Polaris Partners.
ForSight Robotics is a medtech startup developing ORYOM, the first hybrid intraocular robotic ophthalmic platform for automating delicate eye surgeries like cataracts.[1][2][4] It serves eye surgeons and patients worldwide by addressing surgeon fatigue, precision challenges in microsurgery, and access barriers in underserved areas, delivering high-precision, cost-effective procedures that restore vision and improve outcomes.[1][2][4] The company has gained momentum through pre-IPO investor interest and leadership in the growing robotic-assisted eye surgery market, with recent funding trends in robotics startups signaling strong growth potential.[3]
Founded in 2020, ForSight combines expertise from top eye surgeons and robotics pioneers to balance human skill with automation, targeting millions affected by vision loss.[3][4]
ForSight Robotics was founded in 2020 by Daniel Glozman (CEO) and Moshe Shoham (Co-Founder and Chief Scientist), with Dr. Joseph Nathan as Co-Founder, President, and Chief Medical Officer.[3] Moshe Shoham brings prolific experience in medical robotics, while Dr. Nathan's ophthalmology expertise and Glozman's entrepreneurial drive sparked the venture.[3] The idea emerged from the need to automate intricate eye procedures—cataracts affect millions globally—where manual surgery demands extreme precision amid surgeon strain and limited access in remote areas.[2][4] Early traction built on assembling "the world's leading eye surgeons, robotics experts, engineers, and entrepreneurs," culminating in ORYOM's introduction as a brain-powered, heart-driven platform.[1][4]
ForSight rides the surgical robotics wave in ophthalmology, where aging populations drive cataract demand (over 28 million U.S. cases yearly) and robotics address surgeon shortages amid rising procedure volumes.[2] Timing aligns with exploding robotics funding—up in 2025—and market analyses projecting rapid growth in robotic-assisted eye surgery through AI-enhanced precision.[3] Favorable forces include global vision loss epidemics and medtech shifts toward automation, positioning ForSight to democratize elite care and influence standards like hybrid human-robot systems.[1][4] It shapes the ecosystem by pioneering intraocular robotics, potentially accelerating adoption in high-volume, error-prone eye procedures.
ForSight is primed for regulatory milestones, clinical trials, and commercial launches of ORYOM, targeting FDA clearance and global expansion amid 2025-2026 robotics hype.[3] Trends like AI integration and telemedicine will amplify its reach, evolving it from niche innovator to ecosystem leader in accessible eye care. As pre-IPO buzz builds, expect partnerships with hospitals and Big Medtech, restoring not just sight but surgical scalability worldwide—fulfilling its vision of high-precision surgery for all.[1][4]
ForSight Robotics has raised $195.0M across 3 funding rounds. Most recently, it raised $130.0M Series B in June 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2025 | $130.0M Series B | Accel, Eclipse Ventures, Sonder Capital, Jeff Crusey | |
| Jul 1, 2022 | $55.0M Series A | Accel, Borealis Ventures, Eclipse Ventures, Mithril Capital Management, Polaris Partners, Jeff Crusey | |
| Mar 1, 2021 | $10.0M Seed | Accel, Borealis Ventures, Eclipse Ventures, Mithril Capital Management, Polaris Partners, Jeff Crusey |